Health Check: Telix shares rocket after bullish quarterly sales update

Telix Pharmaceuticals (ASX:TLX): It's made ~A$1.7bn in revenue from Illucix, but here's why the best is yet to come!

What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful story? It would have been possible believe back in those days, but it was still far from certain it would be the case. The recent example of Opthea shows biotech is a risky business and…

Health Check: Telix shares rocket after bullish quarterly sales update

Telix’s quarterly sales reflect first revenue from the company’s recent purchase of a US nuclear medicine manufacturer Island Pharma hopes to lift the kimono on its dengue fever trial next month Race Oncology kicks off its cancer-busting, cardioprotective trial Having gleaned all its revenue to date from its US-approved prostate cancer imaging agent Illucix, Telix Pharmaceuticals (ASX:TLX) is starting to reap the benefit of its acquisition of a …

Telix shares rocket 15% on stellar Q1 sales update

Telix Pharmaceuticals Ltd (ASX: TLX) shares are catching the eye on Wednesday morning. At the time of writing, the ASX 200 biotech company's shares are up 15% to $28.95. Telix shares rocket on Q1 update Investors have been buying the company's shares this morning following the release of its first quarter update. According to the release, Telix had another strong quarter and delivered further impressive sales growth over the prior corresponding …

Telix Reports US$186M Q1 Revenue, Up 62% YOY

Telix Reports US$186M Q1 Revenue, Up 62% YOY Melbourne (Australia) | 22 April 2025 Telix today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quarter-o…